Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable

Journal of Clinical Pharmacology

Volumn 40, Issue 6, 2000, Pages 624-633

  Shaw, L M ^a   Korecka, M ^a   Aradhye, S ^a   Grossman, R ^a   Bayer, L ^a   Innes, C ^a   Cucciara, A ^a   Barker, C ^a   Naji, A ^a   Nicholls, A ^b   Brayman, K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Roche Global Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIARRHEA; ETHNIC DIFFERENCE; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; RACE DIFFERENCE; UREMIA;

EID: 0033668361     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.2000.tb05988.x     Document Type: Article

References (22)

1. Variable oral absorption of cyclosporine: A biopharmaceutical risk factor for chronic renal allograft rejection
2. Demographic considerations in tacrolimus pharmacokinetics
3. Post-transplant diabetes mellitus and methyl prednisolone pharmacokinetics in African-American and Caucasian renal transplant recipients
4. Fast and slow methylators: Do racial differences influence risk of allograft rejection?
5. Immunosuppressive therapy in high-risk transplant patients
6. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than Caucasian kidney recipients
7. Pilot study ofmycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients
8. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
9. Pharmacokinetics of mycophenolate mofetil: A short review
10. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function
11. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients
12. The effect of renal insufficiency on mycophenoilic acid protein binding
13. Manual and automated [robotic] high-performance liquid chromatography methods for the determination of mycophenoilic acid and its glucuronide conjugate in plasma
14. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid
15. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics
16. Does plasma protein binding of mycophenolic acid affect its clearance?
17. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function
18. Effect of initial slow graft function on renal allograft rejection and survival
19. Pharmacokinetic-pharmacodynamic relationship for mycophenolic acid in renal transplant patients